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1. Introduction 
The notion of white adipose tissue (WAT) as an active contributor to whole-body 
homeostasis, rather than as a mere fat depot, began to take identity with the discovery of 
leptin in 1994 [1]. This 16 kDa protein secreted by adipocytes was found to be the product of 
the gene obese (ob), which is mutated in a murine form of hereditary obesity. From this 
point on, WAT has been found to produce more than 50 cytokines and other molecules. 
These “adipokines” participate, through endocrine, paracrine, autocrine or juxtacrine 
mechanisms of action, in a wide variety of physiological or physiopathological processes, 
including food intake, insulin sensitivity, vascular sclerotic processes, immunity and 
inflammation [2,3,4]. They are currently considered to play a crucial role in crosstalk among 
the adrenal, immune and central and peripheral nervous systems, among others.  
Obesity, the condition originally motivating the spate of research on WAT, is now regarded 
as a pro-inflammatory state, several markers of inflammation having been found to be 
elevated in obese subjects [5]. It is thought that excess WAT can contribute to the 
maintenance of this state in three ways: through inflammation-inducing lipotoxicity; by 
secreting factors that stimulate the synthesis of inflammatory agents in other organs; and by 
secreting inflammatory agents itself. Adipokines include a variety of pro-inflammatory 
peptides (including TNFα, secretion of which by adipocytes was observed even before the 
discovery of leptin [6]). These pro-inflammatory adipokines appear to contribute 
significantly to the “low-grade inflammatory state” of obese subjects with metabolic 
syndrome [7], a cluster of metabolic abnormalities including insulin resistance, 
dyslipidaemia and alteration of coagulation that is associated with increased risk of cancer, 
type II diabetes, cardiovascular complications and autoimmune inflammatory diseases.  
WAT also produces, possibly as an adaptive response, anti-inflammatory factors such as IL1 
receptor antagonist (which binds competitively to the interleukin 1 receptor without 
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triggering activity within the cell) and IL10 (circulating levels of which are also elevated in 
obese individuals).  
2. Cellular and molecular alterations of white adipose tissue in obesity 
One of the consequences of the production and local release of cytokines and adipokines by 
adipocytes is the recruitment of large numbers of immune cells, including monocytes and T-
lymphocytes, into adipose tissue. In particular, pro-inflammatory cytokine levels and 
macrophage density in visceral fat depots are much higher than in subcutaneous adipose 
tissue. While the mechanisms underlying the recruitment and activation of macrophages in 
adipose tissue remain poorly understood, there is emerging evidence that adipose tissue- 
secreted chemokines are largely responsible for the recruitment, retention and activation of 
macrophage precursors (monocytes) in fat. Monocyte chemoattractant protein-1 (MCP-1) 
has been implicated as one of the major mediators of the monocyte recruitment that occurs 
in adipose tissue, while macrophage colony stimulating factor (M-CSF) is believed to 
mediate the conversion of monocytes to macrophages in adipose tissue. Other candidate 
adipocyte-derived molecules that have also been implicated in macrophage 
recruitment/activation in adipose tissue include free fatty acids and lipoprotein lipase. 
The primary function of resident macrophages of adipose tissue remains still unclear. It 
has been proposed that macrophages clear dead (apoptotic and necrotic) cells. Actually, 
adipocytes undergoing necrosis secondary to hypertrophy may lead to macrophage 
activation (with the accompanying release of inflammatory mediators) and their 
subsequent elimination  from adipose tissue Another potentially important role of 
adipose tissue macrophages is modulation of adipocyte function. Cross-talk between 
adipocytes and macrophages is evidenced by the ability of each cell type to enhance the 
production of protein mediators by the other. For instance, adipocyte conditioned media 
can elicit large increases in the production/release of TNFa, IL-6 and NO by 
macrophages, while TNF-a released from macrophages inhibits the production of 
adiponectin by adipocytes. Likely consequences of this cross-talk between macrophages 
and adipocytes include amplification and perpetuation of the inflammatory phenotype 
that is induced by the expanding mass of body fat. 
In humans, macrophage infiltration is correlated with both adipocyte size and BMI and is 
reduced after surgery-induced weight loss in morbidly obese subjects. There is also a 
preferential infiltration of macrophages into omental vs. subcutaneous fat, a phenomenon 
exaggerated by central. The majority of macrophages in obese adipose tissue aggregates in 
“crown-like structures” completely surrounding dead (necrotic-like) adipocytes and 
scavenging adipocyte debris. 
3. Leptin 
Leptin is a 16 kDa non-glycosylated peptide hormone encoded by the gene obese (ob), the 
murine homologue of the human gene LEP [1]. Structurally, it belongs to the class I cytokine 
superfamily, consisting of a bundle of four α-helices. It is mainly produced by adipocytes, 
and circulating leptin levels are directly correlated with WAT mass. It decreases food intake 
and increases energy consumption by acting on hypothalamic cell populations [8,9], 
inducing anorexigenic factors (CART, POMC) and inhibiting orexigenic neuropeptides 
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(NPY, AGRP and orexin), and leptin levels are negatively correlated with glucocorticoids 
[10] and positively with insulin [11]. Its own synthesis is mainly regulated by food intake 
and eating-related hormones, but also depends on energy status, sex hormones (being 
inhibited by testosterone and increased by ovarian sex steroids) and a wide range of 
inflammation mediators [12, 13] (being increased or suppressed by pro-inflammatory 
cytokines depending on whether their action is acute or chronic). Through the mediation of 
these latter agents, leptin synthesis is increased by acute infection and sepsis. As a result of 
the effects of sex hormones, leptin levels are higher in women than in men even when 
adjusted for BMI, which may be relevant to the influence of sex on the development or 
frequency of certain diseases [14], such as osteoarthritis [56]. Thus leptin appears to act not 
only as an adipostatin, the function in relation to which it was discovered, but also as a 
general signal of energy reserves [2] that is involved in a wide variety of other functions, 
including glucose metabolism, the synthesis of glucocorticoids, the proliferation of CD4+ T 
lymphocytes, cytokine secretion, phagocytosis, regulation of the hypothalamic-pituitary-
adrenal axis, reproduction, and angiogenesis [15]. It can accordingly be described as a 
cytokine-like hormone with pleiotropic actions. 
Leptin exerts its biological actions by binding to its receptors. These are encoded by the gene 
diabetes (db) and belong to the class I cytokine receptor superfamily, which includes 
receptors for IL6, LIF, CNTF, OSM, G-CSF and gp130. Alternative splicings of db give rise to 
six receptor isoforms: the soluble form Ob-Re, which lacks a cytoplasmic domain; four forms 
with short cytoplasmic domains (Ob-Ra, Ob-Rc, Ob-Rd and Ob-Rf); and the long form Ob-
Rb, which is found in almost all tissues and appears to be the only form capable of 
transducing the leptin signal.  
As in the case of other class I cytokine receptors, the main routes by which Ob-Rb appears to 
transmit the extracellular signal it receives are JAK-STAT pathways [16], which involve 
JAK2 phosphorylating tyrosines in the cytoplasmic domain of the receptor. In particular, 
mutation of the intracellular tyrosine Y1138 of murine Ob-Rb prevents STAT3 activation and 
results in hyperphagia, obesity and impaired thermoregulation, and replacing Y1138 with a 
serine residue likewise causes pronounced obesity in knock-in mice. However, since Y1138S 
knock-in mice do not exhibit other defects of db/db mice, such as infertility, the role of 
leptin in the processes that are disrupted in these latter conditions must be independent of 
STAT3 [17]. Indeed, the other two cytoplasmic tyrosines of murine Ob-Rb, Y985 and Y1077, 
have been shown to bind other intracellular signalling molecules [16, 18]. The early studies 
of leptin focused on its anorexigenic action. Both in humans and rodents, leptin levels are 
closely correlated with body mass index, and defects of the genes encoding for leptin and its 
receptors give rise to severe obesity and diabetes. Treating leptin-deficient mice with leptin 
induces a reduction in food intake accompanied by an increase in metabolic rate and weight 
loss. Mutations of these genes in humans appear to be rare, but the cases that are known 
have occurred in families with a high prevalence of morbid obesity; again, leptin 
administration has ameliorated all the problems associated with leptin deficiency. As noted 
in previous sections, leptin participates in the control of food intake by acting on an intricate 
neuronal circuit involving hypothalamic and brainstem nuclei [19], where it integrates a 
variety of different orexigenic and anorexigenic signals. 
Leptin therapy is not an effective treatment for morbid obesity that is not due to congenital 
deficiency of leptin or leptin receptors. In these noncongenital types of obesity, leptin 
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concentrations are already high as a consequence of increased fat mass. The persistence of 
obesity in spite of high leptin levels suggests that high leptin levels can induce leptin 
resistance. This may occur due to a leptin-induced increase of SOCS3, which blocks 
intracellular transmission of the leptin signal [20], but our understanding of leptin resistance 
is still limited.  
 
 
Fig. 1. A schematic representation of white adipose tissue (wat) functions. Besides to be the 
main energy store of the body and the site of synthesis of steroids and prostanoids, wat is 
also a source of a plethora of novel factors that modulate the immune/inflammatory 
response and promote atherosclerosis, vascular dysfunction and insulin resistance.  
Db/db mice, which lack leptin receptors, suffer from thymus atrophy [21], and ob/ob mice, 
which lack leptin, are immunodeficient. Leptin must therefore play a role in immunity. This 
presumably explains why the murine immune system is depressed by acute starvation and 
reduced caloric intake, both of which result in low leptin levels [33], and why this 
depression is reverted by administration of exogenous leptin.  
It promotes phagocyte function [24] and induces the synthesis of eicosanoids [25], nitric 
oxide [26] and several pro-inflammatory cytokines [26] in macrophages and monocytes. It 
increases IFNγ-induced production of nitric oxide synthase in murine macrophages [26]. It 
induces chemotaxis and the release of reactive oxygen species by neutrophils [27, 28]. It 
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influences the proliferation, differentiation, activation and cytotoxicity of natural killer (NK) 
cells [29].  
It may protect dendritic cells from apoptosis and promote their lipopolysaccharide-
induced maturation and a cytokine production profile featuring low levels of IL10 and 
high levels of IL12, TNFα and costimulatory molecules, which favours the proliferation of 
allogeneic CD4+ T cells (whereas leptin receptor deficiency and sequestration of leptin 
have the opposite effects and result in depressed proliferation of allogeneic CD4+ T cells) 
[30]. Finally, it modifies T-cell balance, induces T-cell activation, and alters the pattern of 
T-cell cytokine production by directing T-cell differentiation towards a TH1 response [31, 
32]. 
Leptin also prevents glucocorticoid-induced thymocyte apoptosis, and increases thymic cell 
counts [33]. The low circulating CD4+ T-cell counts, impaired T-cell proliferation and 
impaired release of T-cell cytokines exhibited by young human patients with morbid obesity 
due to congenital leptin deficiency are all ameliorated by administration of recombinant 
human leptin. The fact that several T-cell antigens are expressed aberrantly in both ob/ob 
and db/db mice suggests that leptin may influence the growth, differentiation and 
activation of T cells by interacting with T-cell co-stimulatory antigens such as CTLA4 and 
dipeptidyl peptidase IV [34]. It is possible, however, that in the thymus T cells are affected 
by leptin only indirectly, via other signalling molecules: fetal db/db thymi develop 
normally when transplanted into wild-type hosts; neither the thymus weight and cellularity 
nor the cellular and humoral immune responses of wild-type mice are affected by 
transplantation of bone marrow cells from db/db mice more than by transplantation from 
db/+ mice; and thymus weight and cellularity are decreased when bone marrow cells are 
transplanted from wild-type mice to db/db mice [47].  
A salient aspect of the effects of leptin in the immune system is its action as a pro-
inflammatory cytokine: it is produced by inflammatory cells [35], and leptin mRNA 
expression and circulating leptin levels are increased by a number of inflammatory stimuli, 
including IL1, IL6 and lipopolysaccharide (LPS) [36]. Leptin-deficient mice are less prone 
than non-leptin-deficient mice to develop inflammatory diseases, regardless of whether 
these involve innate or adaptive immunity; reported conditions include experimentally 
induced colitis, experimental autoimmune encephalomyelitis, type I diabetes and 
experimentally induced hepatitis [2]. In the innate case, a reported imbalance between pro- 
and anti-inflammatory cytokines [37] suggests that leptin is able to modify the cytokine 
secretion pattern of monocytes and macrophages through a STAT3-mediated mechanism 
[38]. In the adaptive case, resistance may be due to the above-noted influence of leptin 
deficiency on TH1/TH2 balance [39]. When transferred to T-cell-deficient mice, murine 
CD4+ CD45RBhigh T cells from db/db mice do not induce colitis as rapidly as do 
CD4+ CD45RBhigh T cells from non-db/db mice, which feature leptin receptors [40]. Also, in 
rats with chemically induced intestinal inflammation, circulating leptin levels are elevated, 
and correlate with the degree of inflammation and the development of anorexia, during the 
first day following the induction of inflammation [41]. Serum leptin levels are likewise high 
in human patients with acute ulcerative colitis, in whom inflamed colonic epithelial cells 
secrete leptin into the intestinal lumen, where it is able to activate NFkB [42]. Thus leptin 
appears to play a significant role in intestinal inflammation as well as in the development of 
associated anorexia.  
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Mice in which experimental autoimmune encephalomyelitis (EAE) has been induced by 
inoculation of appropriate self-antigens constitute an animal model of human multiple 
sclerosis, a disease in which leptin levels in serum and cerebrospinal fluid are high and are 
negatively correlated with CD4+ CD25+ regulatory T cells [43]. Ob/ob mice do not develop 
EAE in response to EAE-inducing antigens, but this resistance is abolished by 
administration of leptin, and the abolition of resistance is accompanied by a switch from a 
TH2 to a TH1 pattern of cytokine release [44]. Also, the onset of EAE in wild-type mice is 
preceded by an increase in circulating leptin and is delayed by acute starvation [35]. Of 
particular interest is the finding that during the active phase of EAE leptin is secreted by 
both macrophages and T cells that have infiltrated the central nervous system (CNS), and 
that secretion by activated T cells appears to constitute an autocrine loop sustaining their 
proliferation [35]. By contrast, however, leptin secretion by T cells seems to have at most a 
marginal role in experimentally induced colitis and hepatitis, in which conditions no 
differences have been found between ob/ob and wild-type T cells regarding their ability to 
induce inflammation [45].  
Serum leptin levels increase preceding not only the onset of EAE [35], but also the onset of 
diabetes in female non-obese diabetic (NOD) mice, in which leptin administration augments 
inflammatory infiltrates, increases interferon γ production by peripheral T cells, and speeds 
up the destruction of pancreatic β cells [46]. These latter findings suggest that leptin may 
promote the development of type 1 diabetes through a TH1 response.  
Finally, leptin administration increases both inflammatory and platelet responses in humans 
during caloric deprivation [48], and in WAT-less mice increases T-cell–mediated hepatic 
inflammation [49]. Together with a number of other neuroendocrine messengers, leptin 
appears to play a major role in autoimmune diseases such as rheumatoid arthritis. In 
patients with rheumatoid arthritis, circulating leptin levels are high [51, 52], and leptin 
production is much higher in osteoarthritic cartilage than in normal cartilage [55].  
Of all the connective tissues that compose a skeletal joint, articular cartilage is the most 
damaged by rheumatic disease. Under pathological conditions, control of the balance 
between synthesis and degradation of extracellular matrix by chondrocytes is lost, and the 
production of a host of inflammation mediators by these cells eventually leads to complete 
loss of cartilage structure [53, 54]. The finding that administration of exogenous leptin 
increases IGF1 and TGFβ1 production by rat knee joint cartilage has suggested that high 
circulating leptin levels in obese individuals may protect cartilage from osteoarthritic 
degeneration [55]. However, most of the evidence points the other way: in rheumatoid 
arthritis patients a fasting-induced fall in circulating leptin is associated with CD4+ 
lymphocyte hyporeactivity and increased IL4 secretion [50]; experimental antigen-induced 
arthritis is less severe in leptin-deficient ob/ob mice than in wild-type mice [39]; and in 
cultured chondrocytes type 2 nitric oxide synthase (NOS2) is activated by the combination 
leptin plus IFNγ (though by either without the other) [57], and NOS2 activation by IL1 is 
increased by leptin [58] (nitric oxide has well-documented pro-inflammatory effects on joint 
cartilage, triggering the loss of chondrocyte phenotype, chondrocyte apoptosis, and the 
activation of metalloproteases). Intracellularly, the joint action of IL1 and leptin involves 
JAK2, PI3K, MEK1 and p38.   
A pro-inflammatory effect of leptin on cartilage would be in keeping with the fact that, in 
comparison with men, women have both higher circulating leptin levels and a greater 
propensity to develop osteoarthritis [56]. It would also explain association between obesity 
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and inflammatory conditions, especially those related with alterations of cartilage 
homeostasis.  
4. Adiponectin 
Adiponectin, also called gelatin binding protein 28 (GBP28), adipose most abundant gene 
transcript 1(apM1), and 30 kDa adipocyte complement-related protein (Acrp30, AdipoQ), is 
a 244-residue protein that, as far as is known, is produced prevalently by WAT. It increases 
fatty acid oxidation and reduces the synthesis of glucose in the liver [61]. Ablation of the 
adiponectin gene has no dramatic effect on knock-out mice on a normal diet, but when 
placed on a high-fat, high-sucrose diet they develop severe insulin resistance and exhibit 
lipid accumulation in muscles [62]. Circulating adiponectin levels tend to be low in 
morbidly obese patients and increase with weight loss and with the use of 
thiazolidinediones, which enhance sensitivity to insulin [67].  
Adiponectin acts mainly via two receptors, one (AdipoR1) found mainly in skeletal muscle 
and the other (AdipoR2) in liver (for a third route, see the next section). Transduction of the 
adiponectin signal by AdipoR1 and AdipoR2 involves the activation of AMPK, PPAR (α and 
γ) and presumably other signalling molecules also. Adiponectin exhibits structural 
homology with collagen VIII and X and complement factor C1q, and circulates in the blood 
in relatively large amounts in oligomeric forms (mainly trimers and hexamers, but also a 12-
18-mer form [59]), constituting about 0.01% of total plasma protein. Whether the various 
oligomers have different activities, which would make the effect of adiponectin controlable 
through its oligomerization state, is somewhat controversial and may depend on target cell 
type: although authors working with myocytes reported that trimers activated AMP-
activated protein kinase (AMPK) whereas higher oligomers activated NFκb, it has also been 
reported that 12-18-mers promote AMPK in hepatocytes [60].  
Although adiponectin was discovered nearly at the same time as leptin, its role in protection 
against obesity and obesity-related disorders only began to be recognized some years later. 
It is now beginning to be recognized that, in addition, it has a wide range of effects in 
pathologies with inflammatory components, such as cardiovascular disease, type 2 diabetes, 
metabolic syndrome and rheumatoid arthritis. One indication of a relationship between 
adiponectin and inflammation is provided by the finding that its secretion by cultured 
adipocytes is inhibited by pro-inflammatory cytokines such as IL6 [65] and TNFα [66]. More 
recently, an explanation of how hypoadiponectinaemia might contribute to the development 
of inflammation-related diseases has been suggested by the finding that adiponectin 
promotes the phagocytosis of apoptotic cells (by interacting with calreticulin on the 
phagocyte surface), since the accumulation of apoptotic débris is known to be able to cause 
inflammation and immune system dysfunction [67]. In the remainder of this section we look 
at the relationship of adiponectin to inflammatory processes in several types of pathology. 
Adiponectin has been described as a potent anti-atherogenic factor that protects vascular 
endothelium against atherogenic inflammation through multiple effects on the endothelium 
itself and other vascular structures [63]. It inhibits the adhesion of monocytes to endothelial 
cells, reduces the synthesis of adhesion molecules and tumor necrosis factor, and reduces 
NFκB levels [64]. Subnormal levels of adiponectin have been linked to inflammatory 
atherosclerosis in humans [69], and in animal models they are associated with increased 
vascular smooth cell proliferation in response to injury, increased free fatty acid levels, and 
insulin resistance [70]. The conjunction of pro-diabetic and pro-atherogenic effects of 
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reduced adiponectin levels, as seen in metabolic syndrome, make adiponectin a link 
between obesity and inflammation.  
In contrast to its protective role against obesity and vascular diseases, it appears that in 
skeletal joints adiponectin is pro-inflammatory and involved in matrix degradation. Plasma 
adiponectin levels in rheumatoid arthritis patients are higher than in healthy controls [51] 
(and adiponectin levels in synovial fluid are higher in rheumatoid arthritis patients than in 
patients with osteoarthritis [72]). In human synovial fibroblasts adiponectin selectively 
induces, via the p38 MAPK pathway, two of the main mediators of rheumatoid arthritis, IL6 
and matrix metalloproteinase 1 [71]. Chondrocytes also present functional adiponectin 
receptors, activation of which leads to the induction of type 2 NOS via a signalling pathway 
that involves PI3 kinase; and adiponectin-treated chondrocytes similarly increase IL6, TNFα 
and MCP1 synthesis (but not release of prostaglandin E2 or leukotriene B4). Taken together, 
these results suggest that it may be worth considering adiponectin as a potential target of 
treatment for degenerative joint diseases. On the other hand, the high adiponectin levels of 
patients with rheumatoid arthritis can also be interpreted as an attempt to overcome the 
well-known pro-inflammatory effect of leptin, for example by counteracting the 
pro-inflammatory effects of TNFα and reducing the production of IL6 and CRP in 
rheumatoid arthritis [73].   
In experimental models of liver injury, adiponectin has been reported to have anti-
inflammatory effects: in rodents, adiponectin administration improves liver function in both 
alcoholic and non-alcoholic fatty liver disease as the result of TNF suppression, and in mice 
it reduces liver enzyme levels, hepatomegaly and steatosis [74], attenuates liver fibrosis [75], 
and protects against LPS-induced liver injury [76]. 
Finally, there is also evidence that adiponectin may influence the development of certain 
neoplasias and the course of wound healing [77, 78].  
5. Resistin 
Resistin is a dimeric protein that received its name from its apparent induction of insulin 
resistance in mice. It belongs to the FIZZ (found in inflammatory zones) family (now also 
known as RELMs, i.e. resistin-like molecules). The first member this family to be discovered, 
FIZZ1 (also known as RELMα), is a protein that is found in above-normal levels in the 
bronchoalveolar fluid of mice with experimentally induced asthma [79]. FIZZ2 (RELMβ) 
was discovered in the proliferating epithelium of intestinal crypt [80]. Resistin (FIZZ3) has 
been found in adipocytes, macrophages and other cell types. In rodents, a fourth FIZZ 
protein, RELMγ, has been identified in WAT and haematopoietic tissues [81]. 
As noted above, it has been postulated that resistin mediates insulin resistance, but this role 
may be limited to rodents. Initial enthusiasm for this theory, which provides a direct link 
between adiposity and insulin resistance [83], was quickly quenched by contradictory 
findings in both mice and humans. It nonetheless appears safe to assert that resistin levels 
depend upon both nutritional state and hormonal environment; that they are low during 
fasting and restored by refeeding; and that growth hormone, catecholamines and endothelin 
1 are all able to increase resistin secretion [82].  
5.1 Resistin and inflammation 
That resistin is involved in inflammatory conditions in humans is suggested by its secretion 
in appreciable quantities by mononuclear cells. Also, resistin levels are correlated with those 
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of cell adhesion molecules such as ICAM1 in patients with obstructive sleep apnoea [87], 
and in atherosclerotic patients are positively associated with other markers of inflammation, 
such as soluble TNF-R type II and lipoprotein-associated phospholipase A2 [88]. 
Furthermore, LPS has been reported to induce resistin gene expression in primary human 
and murine macrophages via a cascade involving the secretion of pro-inflammatory 
cytokines [86]; and in human peripheral blood mononuclear cells resistin appears both to 
induce [85] and be induced by [84] IL6 and TNFa  (induction of these cytokines by resistin 
occurring via the NFκB pathway [85]). However, both TNFα and IL6 downregulate resistin 
or have no effect in adipocytes [84].  
A pro-inflammatory role of resistin in atherosclerosis is suggested by reports that in 
vascular endothelial cells it induces the inflammation marker long pentraxin 3 [90] and 
promotes the release of endothelin 1 and production of VCAM1, ICAM1 and monocyte 
chemotactic protein 1 (MCP1) [89]. In murine models of atherosclerosis, resistin is present in 
sclerotic lesions at levels that are proportional to the severity of the lesion [92]. In humans 
resistin is associated with coronary artery calcification, a quantitative marker of 
atherosclerosis [91].   
There are indications that resistin may also be involved in the pathogenesis of rheumatoid 
arthritis: resistin has been found in the plasma and the synovial fluid of rheumatoid arthritis 
patients [92], and injection of resistin into mice joints induces an arthritis-like condition, 
with leukocyte infiltration of synovial tissues, hypertrophy of the synovial layer and pannus 
formation [85]. However, plasma resistin levels in rheumatoid arthritis patients appear to be 
no different from those found in healthy controls [51,85]; and although in some studies of 
rheumatoid arthritis patients resistin levels were higher in synovial fluid than in serum 
(which shows that circulating levels of adipokines do not necessarily reflect the situation in 
the joint), the discrepancy may be due simply to the increased permeability of inflamed 
synovial membrane [93].  
6. Other adipokines 
6.1 Visfatin 
Visfatin is an insulin-mimetic adipokine that was originally discovered in liver, skeletal 
muscle and bone marrow as a growth factor for B lymphocyte precursors (whence its 
alternative name, pre-B-colony enhancing factor, or PBEF). It is up-modulated in models of 
acute lung injury and sepsis. It was re-discovered by Fukuhara et al. [94] using a differential 
display technique to identify genes that are relatively specifically expressed in abdominal 
fat. Circulating visfatin levels are closely correlated with WAT accumulation, visfatin 
mRNA levels increase in the course of adipocyte differentiation, and visfatin synthesis is 
regulated by several factors, including glucocorticoids, TNFα, IL6 and growth hormone. In 
an experimental model of obesity-associated insulin resistance, circulating visfatin levels 
increased during the development of obesity, apparently due solely to secretion by 
abdominal WAT (since visfatin mRNA increased only in this tissue, not in subcutaneous 
WAT or liver). However, visfatin is not only produced by WAT, but also by endotoxin-
challenged neutrophils, in which it prevents apoptosis through a mechanism mediated by 
caspases 3 and 8 [95]. Also, patients with inflammatory bowel diseases have increased 
circulating visfatin levels and increased levels of visfatin mRNA in their intestinal 
epithelium; and visfatin has been shown to induce chemotaxis and the production of IL1β, 
TNFα, IL6 and costimulatory molecules by CD14+ monocytes, and to increase their ability 
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to induce alloproliferative responses in lymphocytes, effects which are mediated 
intracellularly by p38 and MEK1 [96]. Visfatin is therefore certainly pro-inflammatory in 
some circumstances. In addition, circulating visfatin is higher in patients with rheumatoid 
arthritis than in healthy controls [51]. Even though it is currently unclear what is visfatin 
physiological role or relevance in the context of rheumatoid arthritis, it may reflect 
modulation of the inflammatory or immune response by visfatin; or it may forms part of a 
compensatory mechanism that facilitates the accumulation of intra-abdominal fat so as to 
prevent rheumatoid cachexia; or it may simply be an epiphenomenon.  
6.2 Apelin 
Apelin is a bioactive peptide that was originally identified in bovine stomach extracts as the 
endogenous ligand of the orphan G protein-coupled receptor APJ [97]. It is derived from a 
77-amino-acid prepropeptide that is cleaved into a 55-amino-acid fragment and then into 
shorter forms. The physiologically active form is thought to be apelin 36, although the 
pyroglutamylated form of apelin 13, which is also produced endogenously, is more potent. 
Boucher et al. [98] recently found that apelin is produced and secreted by mature human 
and murine adipocytes, and that the apelin mRNA levels found in these cells are similar to 
those found in the stroma-vascular fraction (which contains other cell types present in 
adipose tissue) and in organs such as kidney and heart [98]. In obese humans plasma apelin 
levels are significantly higher than in lean controls [98,100], and that this may be due to 
production by WAT is suggested by the finding that in several murine models of obesity 
above-normal plasma apelin levels are accompanied by above-normal apelin mRNA levels 
in adipocytes [98].  TNFα increases both apelin production in adipose tissue and blood 
plasma apelin levels when administered to mice by intraperitoneal injection [99]. 
Intriguingly, in mice with diet-induced obesity, macrophage counts and the levels of 
pro-inflammatory agents such as TNFα seem to rise progressively in adipose tissue before a 
rise in circulating insulin levels indicates the onset of insulin resistance [101]. So, it could be 
conceivable that in adipocytes there is a substantial regulation of apelin synthesis exerted by 
TNFα, leading to sustained apelin secretion in obesity.  
Thus, one may envisage that over-production of apelin in the obese may be an adaptive 
response that attempts to forestall the onset of obesity-related disorders such as mild chronic 
inflammation, hypertension and cardiovascular dysfunctions. Accordingly, further 
elucidation of the role of apelin is of major interest. 
6.3 Vaspin 
Vaspin (visceral-adipose-tissue-derived serpin) was discovered by Hida et al. [102] as a 
serpin (serine protease inhibitor) that was produced in the visceral adipose tissue of Otsuka 
Long–Evans Tokushima Fatty rats at the age when obesity and plasma insulin 
concentrations reach a peak; thereafter, vaspin production decreased as diabetes worsened 
and body weight fell in untreated mice, but serum vaspin levels were maintained by 
treatment with insulin or pioglitazone. Administration of vaspin to obese mice improved 
glucose tolerance and insulin sensitivity, and reversed altered expression of genes that may 
promote insulin resistance.  
Kloting et al. [103] reported that human vaspin mRNA is not detectable in the adipose tissue 
of normal, lean, glucose-tolerant individuals, but can be induced by increased fat mass, 
decreased insulin sensitivity, and impaired glucose tolerance. The regulation of vaspin gene 
expression seems to be fat depot-specific. The induction of vaspin by adipose tissue may 
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constitute a compensatory mechanism in response to obesity, severe insulin resistance and 
type 2 diabetes.  
7. Conclusions 
It is now clear that adipokines play multiple important roles in the body, and the increasing 
research effort in this area is gradually revealing the intricate adipokine-mediated interplay 
among white adipose tissue, metabolic diseases and inflammatory (auto)immune illnesses. 
Although many issues remain foggy, in this section we outline several possible avenues for 
therapeutic action that this work has already opened.  
There is now a huge amount of data on the promotion of inflammation by high circulating 
leptin levels. It might perhaps be possible to control the amount of bioavailable circulating 
leptin, and hence to prevent leptin-induced inflammation, by means of a soluble, high-
affinity leptin-binding molecule analogous to the soluble TNFα receptors used to treat 
rheumatoid arthritis. Alternatively, it might be possible to block the leptin receptor with 
monoclonal humanized antibodies or mutant leptins that are able to bind to the receptor 
without activating it. An obvious proviso here is that receptors mediating the influence of 
leptin on food intake should not be blocked, lest the patient develop hyperphagia and 
obesity; but the fact that this influence is exerted in the brain, on the other side of the blood-
brain barrier, would seem to make such discrimination possible. At present, little is known 
in this area because current anti-leptin agents were developed to control the adipostatic 
effects of leptin, and hence to cross the blood brain barrier.  
The anti-atherosclerotic and vasoprotective effects of adiponectin are another source of 
inspiration for possible pharmacological approaches to inflammatory diseases. In particular, 
one strategy against diabetes and relevant cardiovascular and metabolic diseases might be 
to tackle the hypoadiponectinaemia associated with these conditions. Given the high levels 
of adiponectin in the blood, exogenous administration of the adipokine itself would 
probably have little effect; but drugs that specifically enhance endogenous adiponectin 
production, such as thiazolidinediones, might well prove to be effective. It should not be 
forgotten, of course, that the primary causes of obesity are generally nutritional and lifestyle 
factors such as overeating and physical inactivity, and that front line treatment of obesity-
related hypoadiponectinemia and obesity-related hyperproduction of detrimental 
adipokines therefore essentially involves the correction of these factors. 
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